HCC1419 Xenograft Model Service for Breast Cancer

The HCC1419 xenograft model provides a powerful in vivo platform for studying HER2-amplified breast cancer and evaluating the efficacy of novel targeted therapies in a clinically relevant context. Alfa Cytology offers comprehensive HCC1419 xenograft model services, leveraging our specialized expertise to accelerate your preclinical drug discovery through high-fidelity modeling and rigorous data analysis.

Overview of HCC1419 Xenograft Model for Breast Cancer

The HCC1419 cell line is a highly valuable human mammary carcinoma model, particularly recognized for its significant amplification and overexpression of the HER2 (ERBB2) oncogene. Originally derived from a primary ductal carcinoma, this model represents the HER2-positive molecular subtype, which is known for its aggressive clinical behavior and high proliferative potential. Unlike some other HER2 models, HCC1419 cells exhibit a distinct genetic background that makes them ideal for investigating resistance mechanisms to current standard-of-care treatments and for screening next-generation anti-HER2 agents, including antibody-drug conjugates (ADCs) and small-molecule kinase inhibitors.

When established in vivo as a xenograft in immunocompromised mice, HCC1419 tumors reliably recapitulate the histological and molecular architecture of human HER2+ breast cancer. The model demonstrates consistent growth kinetics and maintains its genomic hallmarks throughout the study period.

Fig 1. IC50 concentrations of CA, CGA, and Arc-treated breast cancer cells over time. (Schuster C, et al., 2022)

Cell Line Information: HCC1419

The HCC1419 cell line maintains a stable epithelial morphology and high HER2 expression levels, ensuring the biological integrity of the in vivo results.

Alfa Cytology is committed to delivering scientifically rigorous results for your most challenging oncology projects. Our technical team specializes in the precise execution of human tumor xenograft studies, utilizing standardized protocols to ensure high tumor take rates and reproducible growth curves.

Our Services

Workflow of HCC1419 Xenograft Model Construction

Alfa Cytology follows a meticulously standardized workflow to ensure the successful construction of the HCC1419 xenograft model:

• Cell Culture & Preparation: HCC1419 cells are cultured in optimized growth media and harvested during the exponential growth phase. We perform rigorous quality control, including STR authentication and mycoplasma screening, to ensure cell identity and high viability.
• Host Animal Selection: Healthy immunocompromised mice (such as Nude or SCID strains) are selected and allowed to acclimate to our controlled laboratory environment before the study begins.
• Standardized Inoculation: A precisely calibrated suspension of HCC1419 cells is prepared and often combined with a biological matrix carrier to enhance tumor engraftment. The cells are injected in vivo via subcutaneous or orthotopic mammary fat pad routes.
• Longitudinal Monitoring: Following inoculation, tumor growth is systematically tracked. We use precision calipers to record tumor dimensions and monitor animal body weight, establishing a reliable growth curve that adheres to strict welfare guidelines.
• Randomization & Grouping: Once tumors reach a consistent and statistically relevant volume, animals are randomized into treatment and control cohorts to ensure balanced distribution before therapeutic dosing commences.

Fig 2. HCC1419 Xenograft Model Construction Workflow

Case Study - HCC1419 Xenograft Model Development

In a recent validation study conducted at Alfa Cytology, the HCC1419 xenograft model was utilized to evaluate the efficacy of a novel HER2-targeted ADC candidate. Our technical team achieved highly reproducible tumor engraftment and uniform growth kinetics across all cohorts, providing a clear window for therapeutic observation. The in vivo results revealed significant, dose-dependent tumor growth inhibition compared to the control group.

Why Choose Alfa Cytology?

• HER2 Specialty Expertise: Proven track record in establishing and characterizing HER2-amplified models.
• Technical Precision: Standardized inoculation and monitoring protocols that minimize experimental variability.
• Comprehensive Support: Full capacity for downstream analysis, including IHC for HER2 expression, PK/PD correlation, and histopathology.
• Scientific Integrity: Commitment to high-fidelity data and transparent communication throughout the study lifecycle.

Contact Us

Ready to advance your HER2+ breast cancer research with a high-performance HCC1419 xenograft model? Our senior scientists at Alfa Cytology are available to provide tailored experimental designs and technical insights to help you meet your drug discovery milestones. Please reach out to us today to discuss your project requirements, or contact us directly to request a comprehensive consultation and quotation.

For research use only. Not intended for any clinical use.